Efficacy and Safety of glecaprevir/pibrentasvir for the Pangenotypic Treatment of Chronic Hepatitis C in former intravenous drug users: Subanalysis from a Spanish Real-World Cohort (Hepa-C)

Conference Reports for NATAP

The International Liver Congress™
EASL - European Association for the
Study of the Liver
2019 April 10-14
Vienna Austria


Efficacy and Safety of glecaprevir/pibrentasvir for the Pangenotypic Treatment of Chronic Hepatitis C in former intravenous drug users: Subanalysis from a Spanish Real-World Cohort (Hepa-C)

	Reported by Jules Levin EASL 2019 April 10-14 Vienna